Actinogen Medical (ASX:ACW) - Share price, News & Analysis

ACW fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ACW Stock Overview

Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological diseases in Australia.

Risk Analysis

Earnings have declined by 1.8% per year over past 5 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$2M)

+ 1 more risk

Actinogen Medical Competitors

Prescient Therapeutics

ASX:PTX

AU$107.9m

Immutep

ASX:IMM

AU$328.8m

Aroa Biosurgery

ASX:ARX

AU$287.9m

Orthocell

ASX:OCC

AU$72.9m

Price History & Performance

Summary of all time highs, changes and price drops for Actinogen Medical
Historical stock prices
Current Share Price	AU$0.071
52 Week High	AU$0.20
52 Week Low	AU$0.055
Beta	2.63
1 Month Change	-27.55%
3 Month Change	-20.23%
1 Year Change	-19.32%
3 Year Change	446.15%
5 Year Change	1.43%
Change since IPO	-91.34%

Recent News & Updates

Apr 07

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Actinogen Medical...

Shareholder Returns

	ACW	AU Biotechs	AU Market
7D	-1.4%	0.5%	-1.2%
1Y	-19.3%	-8.0%	-0.009%

Return vs Industry: ACW underperformed the Australian Biotechs industry which returned -9% over the past year.

Return vs Market: ACW underperformed the Australian Market which returned 0.5% over the past year.

Price Volatility

Is ACW's price volatile compared to industry and market?
ACW volatility
ACW Average Weekly Movement	13.9%
Biotechs Industry Average Movement	9.9%
Market Average Movement	9.3%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	4.2%

Stable Share Price: ACW is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ACW's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Steve Gourlay	https://www.actinogen.com.au

Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer’s disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer’s disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects.

Actinogen Medical Fundamentals Summary

How do Actinogen Medical's earnings and revenue compare to its market cap?
ACW fundamental statistics
Market Cap	AU$126.35m
Earnings (TTM)	-AU$7.35m
Revenue (TTM)	AU$1.93m

65.7x

P/S Ratio

-17.2x

P/E Ratio

Is ACW overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACW income statement (TTM)
Revenue	AU$1.93m
Cost of Revenue	AU$0
Gross Profit	AU$1.93m
Other Expenses	AU$9.29m
Earnings	-AU$7.35m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0041
Gross Margin	100.00%
Net Profit Margin	-380.15%
Debt/Equity Ratio	0%

How did ACW perform over the long term?

See historical performance and comparison

New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Actinogen Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

16.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Actinogen Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Actinogen Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-1.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ACW is currently unprofitable.

Growing Profit Margin: ACW is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ACW is unprofitable, and losses have increased over the past 5 years at a rate of 1.8% per year.

Accelerating Growth: Unable to compare ACW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).

Return on Equity

High ROE: ACW has a negative Return on Equity (-29.92%), as it is currently unprofitable.

Financial Health

How is Actinogen Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ACW's short term assets (A$22.6M) exceed its short term liabilities (A$955.5K).

Long Term Liabilities: ACW's short term assets (A$22.6M) exceed its long term liabilities (A$126.8K).

Debt to Equity History and Analysis

Debt Level: ACW is debt free.

Reducing Debt: ACW has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACW has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ACW has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 1.3% each year.

Dividend

What is Actinogen Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACW's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ACW has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure

CEO

Steve Gourlay (61 yo)

1.17yrs

Tenure

AU$271,068

Compensation

Dr. Steven G. Gourlay, also known as Steve, MBBS (M.D.), Ph D., FRACP, M.B.A., serves as Chief Executive Officer at Actinogen Medical Limited since March 15, 2021 and as its Managing Director and Director...

CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD192.68K) is below average for companies of similar size in the Australian market ($USD287.06K).

Compensation vs Earnings: Insufficient data to compare Steve's compensation with company performance.

Leadership Team

Experienced Management: ACW's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Experienced Board: ACW's board of directors are considered experienced (4.4 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ACW insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30